Functional analysis of a dominant-negative ΔeTS TEL/ETV6 isoform

Biochemical and Biophysical Research Communications

Volumn 317, Issue 4, 2004, Pages 1128-1137

  Sasaki, Ko ^a   Nakamura, Yuka ^a   Maki, Kazuhiro ^a   Waga, Kazuo ^a   Nakamura, Fumihiko ^a   Arai, Honoka ^a   Imai, Yoichi ^b   Hirai, Hisamaru ^b   Mitani, Kinuko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Dominant negative effects; Erythroid differentiation; ETS; Isoform; Leukemic transformation; Myelodysplastic syndrome; Sequestration; TEL; Tumor suppressor

Indexed keywords

ANIMAL CELL; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL GROWTH; CERCOPITHECIDAE; CYTOPLASM; EMBRYO; ERYTHROID CELL; ERYTHROLEUKEMIA CELL; EXON; FIBROBLAST; GENE; GENE FUNCTION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TEL GENE; WILD TYPE;

ALTERNATIVE SPLICING; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; COS CELLS; CYTOPLASM; DIMERIZATION; DNA-BINDING PROTEINS; ERYTHROCYTES; GENES, DOMINANT; HELA CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; NIH 3T3 CELLS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ETS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 1942451767     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.172     Document Type: Article

References (26)

1. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316.
2. Wang L., Hiebert S.W. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene. 20:2001;3716-3725.
3. Lopez R.G., Carron C., Oury C., Gardellin P., Bernard O., Ghysdael J. TEL is a sequence-specific transcriptional repressor. J. Biol. Chem. 274:1999;30132-30138.
4. Martinez R., Golub T.R. Blood. 96:2000;453a.
5. Fenrick R., Wang L., Nip J., Amann J.M., Rooney R.J., Walker-Daniels J., Crawford H.C., Hulboy D.L., Kinch M.S., Matrisian L.M., Hiebert S.W. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol. Cell. Biol. 20:2000;5828-5839.
6. Wang L.C., Kuo F., Fujiwara Y., Gilliland D.G., Golub T.R., Orkin S.H. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J. 16:1997;4374-4383.
7. Wang L.C., Swat W., Fujiwara Y., Davidson L., Visvader J., Kuo F., Alt F.W., Gilliland D.G., Golub T.R., Orkin S.H. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12:1998;2392-2402.
8. Waga K., Nakamura Y., Maki K., Arai H., Yamagata T., Sasaki K., Kurokawa M., Hirai H., Mitani K. Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells. Oncogene. 22:2003;59-68.
9. Potter M.D., Buijs A., Kreider B., van Rompaey L., Grosveld G.C. Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. Blood. 95:2000;3341-3348.
10. Gu X., Shin B.H., Akbarali Y., Weiss A., Boltax J., Oettgen P., Libermann T.A. Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6. J. Biol. Chem. 276:2001;9421-9436.
11. Arai H., Maki K., Waga K., Sasaki K., Nakamura Y., Imai Y., Kurokawa M., Hirai H., Mitani K. Functional regulation of TEL by p38-induced phosphorylation. Biochem. Biophys. Res. Commun. 299:2002;116-125.
12. Maki K., Mitani K., Yamagata T., Kurokawa M., Kanda Y., Yazaki Y., Hirai H. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood. 93:1999;3216-3224.
13. Poirel H., Oury C., Carron C., Duprez E., Laabi Y., Tsapis A., Romana S.P., Mauchauffe M., Le Coniat M., Berger R., Ghysdael J., Bernard O.A. The TEL gene products: nuclear phosphoproteins with DNA binding properties. Oncogene. 14:1997;349-357.
14. Friend C., Scher W., Holland J.G., Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA. 68:1971;378-382.
15. Marks P.A., Rifkind R.A. Erythroleukemic differentiation. Annu. Rev. Biochem. 47:1978;419-448.
16. Harada H., Kondo T., Ogawa S., Tamura T., Kitagawa M., Tanaka N., Lamphier M.S., Hirai H., Taniguchi T. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene. 9:1994;3313-3320.
17. Foulkes N.S., Sassone-Corsi P. More is better: activators and repressors from the same gene. Cell. 68:1992;411-414.
18. Lazar M.A., Hodin R.A., Cardona G., Chin W.W. Gene expression from the c-erbAα/Rev-ErbAα genomic locus. Potential regulation of alternative splicing by opposite strand transcription. J. Biol. Chem. 265:1990;12859-12863.
19. Artandi S.E., Merrell K., Avitahl N., Wong K.K., Calame K. TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. Nucleic Acids Res. 23:1995;3865-3871.
20. Nakabeppu Y., Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell. 64:1991;751-759.
21. Foulkes N.S., Borrelli E., Sassone-Corsi P. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell. 64:1991;739-749.
22. Descombes P., Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell. 67:1991;569-579.
23. Tanaka T., Tanaka K., Ogawa S., Kurokawa M., Mitani K., Nishida J., Shibata Y., Yazaki Y., Hirai H. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J. 14:1995;341-350.
24. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn. J. Clin. Oncol. 33:2003;153-160.
25. Hirai H. Molecular pathogenesis of MDS. Int. J. Hematol. 76(Suppl. 2):2002;213-221.
26. Hosoya N., Miyagawa K., Mitani K., Yazaki Y., Hirai H. Mutation analysis of the WT1 gene in myelodysplastic syndromes. Jpn. J. Cancer Res. 89:1998;821-824.